919366-49-7

Upstream product

• 919366-47-5 1-benzyloxycarbonyl-6-cyclohexylmethyl-3-(2,6-dichlorobenzyl)-5,6-dihydro-2-methyl-4-pyridone 
• 919366-45-3 4-cyclohexylmethoxy-3-(2,6-dichlorobenzyl)-2-methylpyridine 
• 190906-91-3 3,4-dihydro-2-methyl-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester 
• 620-08-6 4-methoxypyridine 
• 478246-05-8 3-(2,6-dichlorobenzyl)-2-methylpyridin-4(1H)-one 
• 909867-62-5 1-benzyloxycarbonyl-3-((2,6-dichlorophenyl)(methylsulfonyloxy)methyl)-2,3-dihydro-2-methylpyridin-4(1H)-one 
• 909867-58-9 1-benzyloxycarbonyl-3-((2,6-dichlorophenyl)hydroxymethyl)-2,3-dihydro-2-methylpyridin-4(1H)-one 

Relevant academic research and scientific papers

4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI

Bacterial FAS provides essential fatty acids for use in the assembly of key cellular components. Among them, FabI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. It is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Until today, various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds. To discover novel small-molecular FabI inhibitors, we initially screened our compound library for inhibitory activity toward FabI of Escherichia coli. And discovered 4-pyridone derivatives as a lead compound. Structure optimization studies yielded 4-pyridone derivatives 7n having strong FabI-inhibitory and antibacterial activities against Staphylococcus aureus. There have been no reports concerning 4-pyridone derivatives as FabI inhibitor.